Hematopoietic tissues are the targets of numerous xenobiotics. Clinical hematotoxicity is either a decrease or an increase in peripheral blood cell counts in one or more cell lineages-a cytopenia or a cytosis, respectively-that carries a risk of an adverse clinical event. The purpose of in vitro hematotoxicology is the prediction of these adverse hematologic effects from the effects of the toxicants on human hematopoietic targets under controlled experimental conditions in the laboratory. Building on its important foundations in experimental hematology and the wealth of hematotoxicology data found in experimental oncology, this field of alternative toxicology has developed rapidly during the past decade. Although the colony-forming unit-granulocyte/monocyte neutrophil progenitor is most frequently evaluated, other defined progenitors and stem cells as well as cell types found in the marrow stroma can be evaluated in vitro. End points have been proposed for predicting toxicant exposure levels at the maximum tolerated dose and the no observable adverse effect level for the neutrophil lineage, and several clinical prediction models for neutropenia have developed to the point that they are ready for prospective evaluation and validation in both preclinical species and humans. Known predictive end points are the key to successful comparisons across species or across chemical structures when in vitro dose-response curves are nonparallel. Analytical chemistry support is critical for accurate interpretation of in vitro data and for relating the in vitro pharmacodynamics to the in vivo pharmacokinetics. In contrast to acute neutropenia, anemia and acute thrombocytopenia, as well as adverse effects from chronic toxicant exposure, are much more difficult to predict from in vitro data. Pharmacologic principles critical for clinical predictions from in vitro data very likely will apply to toxicities to other proliferative tissues, such as mucositis.
The field of hematotoxicology includes the study of adverse effects of toxicants on mature blood cells and also the precursor cells in the hematopoietic (blood forming) tissues. There are established techniques for assessing adverse effects of xenobiotics on mature blood cells. More recently, the availability of recombinant hematopoietic growth factors makes possible the evaluation of adverse effects against the bloodforming precursor cells as well. Thus, it is now possible to study human hematotoxicology in the preclinical setting. Because it is possible to study the effects of a toxicant on its actual target cell, it seems reasonable to expect in vitro hematotoxicology to be highly predictive.
Fundamentally, toxicology has two goals: identification of the tissues that are susceptible to the toxic effects of the xenobiotic and determination of the level of acute and chronic exposures (doses) that these tissues can tolerate without clinical consequences. The first goal is qualitative; it necessarily involves comparative toxicology in multiple tissues. This comparison is most efficiently completed in vivo where all organs can be exposed simultaneously. A similar evaluation performed ex vivo necessarily requires the assay of multiple human tissues under identical conditions, which at the present time is not technically possible. The estimation of the acceptable level of human exposure from in vitro hematotoxicology data assumes that the toxicant's most potent effects are toward the bone marrow, i.e., hematopoietic tissue is the most sensitive of the human tissues to toxicity. By its nature, hematotoxicology complements, refines, and actually improves standard toxicology testing (usually in vivo), which still is required to identify hematopoiesis as the most likely tissue target of the toxicant in humans. The second goal is quantitative and estimates the level of toxicant exposure that can be tolerated by the target tissue. This is critical for accurate risk assessment and establishment of reasonable regulatory limits on exposure. In this case, ex vivo evaluation must involve evaluation of toxicity to only the target tissue or cells derived from it and in vitro hematotoxicology meets this second goal.
The laboratory techniques for evaluating the effects of a toxicant on human hematopoietic tissue are relatively straightforward, and there is a wealth of data on the toxic effects of xenobiotics on hematopoietic target cells. Most laboratories have the capability of performing all of the ex vivo tests described here. In contrast, the interpretation of the data and the quantitative prediction of the acceptable level of clinical exposure from the data are much more difficult. It is this latter arena in which we have specialized. We have investigated prediction models that translate the data into predicted hematologic perturbations as a function of toxicant exposure levels. The goal in the regulatory setting usually emphasizes the prediction of two levels of exposure: the highest dose that will not cause a dinically adverse effect and the dose that causes maximally tolerated, reversible perturbations in peripheral blood counts. The former is often termed the no observable adverse effect level (NOAEL), whereas the latter is termed the maximum tolerated dose (MTD). Human exposure at the MTD is undesirable except for anticancer agents; with this exception, permissible exposure limits (PELs) are set for all regulated products from the NOAEL. Substantial pharmacologic issues arise during the prediction of clinical outcomes from in vitro data. Ex vivo assays determine the concentration and exposure duration that cause toxicity. In contrast, the regulation of human exposure requires that decisions be based on units of dose or dose intensity (i.e., mg/m2 or mg/kg per unit of time). The prediction of a dose that produces the in vitro concentration-time-effect relationship in vivo involves pharmacokinetics-the disposition of xenobiotic throughout the body. By analogy to animal and clinical toxicology, in vitro hematotoxicology aims to determine the no observable adverse effect concentration (NOAEC) and the maximum tolerated concentration (MTC) of toxicant under a specific schedule of exposure. The pharmacokineticist can then calculate the NOAEL and MTD doses that produce these NOAECs and MTCs. The NOAEC and the MTC are two end points useful in regulatory science sought during in vitro hematotoxicology studies.
The success to date lies primarily in the identification of the in vitro inhibition concentration value that is the MTC. An international validation study sponsored by the European Centre for the Validation of Alternative Methods (ECVAM) is underway to evaluate the predictive value of this putative MTC for clinical neutropenia (1) . Results (8) (9) (10) , and the burst-forming unit-erythroid (BFU-E), which produces large, multifocal colonies of hemoglobinized cells in response to erythropoietin plus cytokines with burst-promoting activity (9, (11) (12) (13) (14) (15) (16) (17) (18) (19) . The megakaryocytic lineage contains the CFU-megakaryocyte (CFU-Mk) (also called CFU-Meg) (20) (21) (22) , which responds to many cytokines, including the c-mpl ligand (23) (24) (25) (26) (27) (28) (29) (30) . By analogy to BFU-E, several laboratories report a BFU-megakaryocyte, which forms large, multifocal colonies (31, 32 recloning (43) (44) (45) (46) (47) (48) (49) (50) . The long-term culture-initiating cell (LTC-IC) is a cell with multilineage potential found at low frequency in the marrow, probably positioned prior to the HPP-CFC in myelopoiesis (51) (52) (53) (54) . LTC-IC cells exhibit several characteristics of stem cells, including some capability of self-renewal, maintenance of both lymphopoiesis and myelopoiesis, and long-term reconstitution of a lethally irradiated host (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) . Bone Marrow Stroma In contrast to the proliferation and expansion of tissue mass by hematopoietic cells, the primary function of the stroma is the nurture and support of developing blood cells (52, (65) (66) (67) . However, there is a stromal colony-forming unit called CFUfibroblastoid (CFU-f), which produces a colony composed of adherent cells exhibiting morphologic features of fibroblasts, adipocytes, and other stromal elements (65, 68 (106, (117) (118) (119) (120) (121) (122) (123) (124) (78, 81, 83, 84, 106, (125) (126) (127) (128) (129) (130) (131) (132) (133) (134) (135) (136) (131, 132, 146, 147) .
Drug exposure levels that inhibit colony formation by approximately 50% do not cause neutropenia clinically (129, 148) . It is likely that the in vitro and in vivo data fail to correlate at these mildly toxic levels of exposure because the hyperplastic response of the marrow can compensate for this magnitude of progenitor loss. For example, there may not be any hematologic consequence from a 2-fold reduction in the frequency of CFU-GM if balanced by a 2-fold increase in marrow cellularity (no net gain in total CFU-GM). A direct correlation may exist between the decreases in donogenic survival and absolute neutrophil counts only when toxicant levels cause such a severe lesion in the progenitor population that marrow hyperplasia cannot compensate.
In vitro assays can also be used to investigate cytopenias caused by noncytotoxic xenobiotics. For example, substances that reduce the number of differentiated blood cells produced per progenitor would be expected to decrease the size of the donal colonies (the number of cells per colony), but not the number of colonies. Colonies that resemble CFU-GM colonies but are too small are named clusters. Thus, reduced CFU-GM colony formation accompanied by a shift in the distribution of colony size toward dusters argues against destruction of the progenitor. Trichothecene mycotoxins appear to shift the balance between proliferation and differentiation toward the latter (113) (114) (115) . Interferons, the transforming growth factor beta (TBF-P) family, and tumor necrosis factors inhibit colony formation by CFU-GM, CFU-GEMM, and HPP-CFC (149) (150) (151) (152) (153) (154) (155) (156) Toxicant-induced anemia is also difficult to predict from erythroid progenitor assays. Because erythrocytes circulate with a relatively long half-life, an acute toxicantinduced disruption of erythropoiesis is probably insufficient to cause anemia. For example, dipyrone inhibited not only CFU-GEMM and CFU-GM but also BFU-E in the presence of serum from a patient with drug-induced agranulocytosis and thrombocytopenia but not anemia (157) . Also, ceftazidime is an equally potent inhibitor of BFU-E and CFU-GM, although it is clinically associated with agranulocytosis (158) .
The most difficult hematotoxicity to predict with in vitro assays is the progressive loss of one or more blood cell lineages during chronic exposure to a toxicant: agranulocytosis, pancytopenia, and aplastic anemia. In some cases the toxicity leaves a permanent dysfunction, while in other cases the toxicity resolves after identification and removal of the toxicant. The distinction between irreversible aplasias like aplastic anemia and the progressive yet usually reversible aplasias like agranulocytosis is important for proper application of in vitro assays. In practice, toxicity may not be definable as reversible or irreversible if the toxic insult cannot be identified or if the degree of permanent damage is insufficient to cause permanent symptoms. In the cases of irreversible marrow damage after multiple toxicant exposures, it is often impossible to know whether toxicity would have occurred after a single exposure.
Progressive yet reversible xenobioticinduced cytopenia generally indicates a direct effect of toxicant or metabolite on hematopoietic cell types. CFU-GM levels in patients with drug-induced agranulocytosis are depressed relative to controls (91, (159) (160) (161) (162) (163) (164) , and inhibition of myeloid and erythroid progenitors is a likely mechanism for beta-lactam-induced agranulocytosis (158) and contributes to phenylhydrazine-induced anemia (10) . In these cases the in vitro progenitor assays correctly identified the mechanism of myelosuppression. Hypersensitivity of progenitors from susceptible individuals to the toxicant or a toxic metabolite can be demonstrated with progenitor assays (161, (165) (166) (167) (168) (169) (170) (171) (168) . Otherwise, the effects of inhibitory cytokines released by mature T cells and monocytes in response to toxicant may be measured instead, which would be a toxicity to the mature blood cell compartment rather than the progenitor compartment. Unfortunately, in many cases when the immune system contributes to hematotoxicity, in vitro studies using marrow from normal donors are not informative and in fact are usually inconclusive (167, 170, 177) .
It is encouraging that several laboratories arrived independently at similar assay conditions for quantifying toxicity to hematopoietic progenitors (1, (81) (82) (83) (84) (85) 178, 179) .
Microculture techniques for progenitors are also available when xenobiotic is in short supply (180) .
Toxicity to Bone Marow Stroma
The microenvironment is a target for toxicant injury (90) , and assays of stromal function have been used to investigate the effects of toxicant exposure. Bone marrow stroma is more sensitive than hematopoietic progenitors to the toxicity of acute neutron irradiation but less sensitive to X rays, and hematopoietic stem cell and stromal cell repopulation, but not progenitor survival, are dependent on dose rate (109, 112, 124, (181) (182) (183) (184) . Long-term bone marrow cultures based on Dexter's method (69) have been used to investigate the agranulocytosis associated with ceftazidime and other agents (82, 158) . In addition, the CFU-f is potentially a dose-limiting cell type for radiation and some quinones of benzo[a]pyrene (183) (184) (185) . CFU-f is the most sensitive progenitor to AZT toxicity, and AZT causes perturbations in parameters of long-term bone marrow assays at clinically relevant concentrations (186) . Both conventional and high-dose cancer chemotherapies cause permanent damage to the marrow microenvironment (111, 148, (187) (188) (189) (190) (191) (192) . However, clinical hematology parameters can recover and even normalize in spite of continuing in vitro measurements of impaired marrow function (148, 182, (189) (190) (191) (192) (193) (194) (195) of the level of toxicant exposure (X axis, Four independent parameters describe acute hematologic toxicity in vivo. In leukocytosis, the parameters usually in concentration units) using a clinied to the maximum increase in leukocyte counts, time to the maximum, duration of the maximum, and time ically relevant duration of exposure ( Figure   ry . In vitro hematotoxicology can be focused on the prediction of these four parameters in the human prior to 2A). The next step is to translate this in 31 human exposure. Initial efforts have focused on validation of in vitro systems for predicting the severity of vitro data into cinical language and predict ophil nadir after acute (preferably single dose) exposure. ** indicates the time of acute toxicant exposure.
the clinical consequences of toxicant exposure. However, the way this goal has been ransduction or destroyed progenitors. toxicity to all of the cell types in the lineage phrased implies a subtle distinction from w mechanism-independent toxicol-but only the in vitro end point from the the conventional purpose of toxicology generally useful and advantageous assay of the actual target cell population studies. Traditionally, the question is one of ecause it prevents assay proliferation will be the most likely predictor of clinical classification: Is this compound a hematome, in which a new assay must be cre-toxicity. Given data from assays of mature toxicant? However, it seems reasonable to r each mechanistic dass that must be blood cell lysis and dysfunction, progenitor assume that any toxicant will be a hematoed, and because it can contribute to survival and function, and stem cell and toxicant if the other tissues of the body can ulation of new products with poorly stromal cell function, how does one predict tolerate high enough exposure levels. tood mechanisms ofaction.
what will be the clinical manifestation of Certainly there will be compounds that e goal of in vitro hematotoxicology is toxicant exposure?
inhibit CFU-GM in vitro but do not cause diction of these four parameters (in It is a well-established principle of in neutropenia, because exposure levels never Id points) from end points obtained vivo toxicology that the adverse effects of reach a high enough level: for example, the ssays of human hematopoietic func-exposure are determined by the most sensi-nonmyelosuppressive nucleoside analog ter in vitro exposure to the toxicant tive of the exposed tissues. The most sensi-dideoxycytidine is in fact toxic to CFU-Mk ). Different in vitro end points, and tive tissue is called the dose-limiting tissue, and CFU-GEMM in vitro (116, 144, 145 complicated data interpretation (87, 88) . For example, it is common practice to compare a new compound with a reference compound of known hematotoxicity in vitro. Suppose one obtains data from such a study that shows a crossing of the concentration-response curves and it cannot be explained by differential chemical stability (Figure 3) . From these data, can one predict whether humans can tolerate higher, the same, or lower levels of the investigational compound than the reference compound? In other words, should the PEL be higher or lower than the reference compound? If one knows that the IC90 is the MTC and that grade 3 to 4 neutropenia is an acceptable risk of human exposure (e.g., a cancer drug), then clearly the tolerated AUC is higher for the investigational product than for the reference compound. Assuming equivalent pharmacokinetics, the PEL can then be set higher for the new product than for the reference product. In contrast, if the IC35 is the NOAEC and neutropenia is not an acceptable consequence of exposure to this product, the opposite conclusion would be reached. The PEL for the investigational product should be set lower than the reference product because its IC35 is lower. This theoretical example illustrates how the interpretation of the in vitro data depends on the intended use of the product. For one use the PEL can be higher, whereas for another use it must be lower. This example also suggests how to choose a least hematotoxic analog from in vitro data when the analogs do not exhibit parallel curves. The least toxic analog is that with the least inhibition in an appropriate in vitro assay at the end point most relevant to the product's intended use. Such data would be impossible to interpret without these X-axis concepts.
The identical issue arises when using in vitro hematotoxicology to directly compare human toxicant sensitivity to that of the preclinical animal species in which the product is tested in vivo. In this case, the question is whether the preclinical toxicology species under-or overestimates human PELs for myelosuppressive compounds. If the direct comparison results in parallel curves ( Figure 4A ) then this question is easily answered. The human:animal ratio at any IC value will provide an estimate of the difference in tolerance of the compound; and, because the IC50 is the most accurately determined point on these curves, the IC50 ratios should be used. However, consider the more typical case of nonparallel curves across species ( Figure 4B) and plasma protein drug binding, the doses that achieve these AUCs in the plasma of exposed humans can be determined. However, the models can only be applied to compounds that are expected to show dose-limiting neutropenia. This is a critical assumption for in vitro hematotoxicology, and in vivo toxicology studies must indicate that neutrophil precursors are the dose-limiting target. If the dose-limiting toxicity of the investigational product was e.g., cardiotoxicity, determination of AUC at the MTC for CFU-GM would overestimate human tolerance and jeopardize patient safety. Some studies have used the 1C70 instead of the 1C90 as the MTC, and these two end points will be compared during some of the ongoing studies. The IC70 may be more appropriate when estimating PELs for products that will be used in patients with impaired marrow function. Prospective evaluation of these models will be critical in gaining acceptance, and Phase I clinical trials (dose-escalation trials) of antineoplastic agents provide an excellent opportunity for such an evaluation. The following models focus on the prediction of MTD; prediction of the NOAEL would simply substitute the IC35 or other NOAEC end point for the 1C90. Prediction Model 1 is the simplist model. It can be used if human pharmacokinetic parameters are unknown or cannot be determined. Model 1 has the greatest level of uncertainty because it incorporates only pharmacodynamics. It is based on the idea that neutrophil progenitors can serve as a sentinel tissue for interspecies comparisons. Large interspecies differences in toxicant disposition (AUC as a function of dose) could lead to significant errors in the predicted MTD.
Step 1: determine the MTD in an animal model; step 2: determine the toxicity differential between the animal and human dose-limiting progenitor based on IC90 values; step 3: adjust the animal MTD for the IC90 differential; and step 4: adjust the MTD again for differences in free drug concentration between the animal and human (e.g., protein binding).
Prediction Model 2 can be used when the AUC cannot be measured at the IC90 for the human progenitor but human pharmacokinetic parameters are known or can be predicted. This model assumes the marrow toxicant causes an AUC-dependent cytotoxicity. The model adjusts the plasma AUC at the MTD in the animal studies for species differentials in drug tolerance and plasma protein drug binding.
Step 1: determine the plasma AUC at the MTD in an animal model; step 2: determine the toxicity differential between the animal and human dose-limiting progenitor based on IC90 values; step 3: adjust the animalderived plasma AUC by the 1C90 differential; step 4: adjust the plasma AUC for differences in free drug concentration between species; and step 5: using human pharmacokinetic parameters or estimated parameters, calculate the dose that gives the predicted AUC.
Prediction Model 3 aims to predict the actual human MTD for the neutrophil lineage. It should be the most accurate prediction model because it incorporates both human pharmacodynamics and pharmacokinetics.
Step 1: identify the most sensitive neutrophil progenitor in human bone marrow; step 2: determine the IC90 for the dose-limiting human progenitor; step 3: derive the in vitro AUC at the IC90 by integrating the Cx t curve; B and step 5: using human pharmacokinetic parameters or estimated parameters, calculate the dose that gives the predicted AUC. Summary Although our knowledge of how to use in vitro hematotoxicity data is in its infancy, these examples illustrate the progress that has been made by assessing exactly what end point is needed, i.e., what clinical end point should be predicted. The realization that X-axis rather than Y-axis end points are required for prediction was in a sense a breakthrough that has made it possible to propose clinical prediction models for prospective evaluation and validation (1, 88, 129) . A second important breakthrough was our realization that predicting neutropenia actually involves the prediction of four independent parameters that, when taken together, describe clinical neutropenia: severity at nadir, time to nadir, duration of nadir, and time to recovery (84, 88) . Progress to date has been exclusively in the prediction of the severity of neutropenia (88, 129) . We are not aware that any progress that has been made in predicting the other parameters from in vitro data. Therefore, assays for CFU-GM and other granulocyte progenitors can be considered useful for investigating the cellular mechanism underlying the severity of reversible neutropenia and for determining the level of toxicant exposure that will be associated with grade 3 to 4 neutropenia. The investigation of the other parameters of neutropenia with in vitro assays should be considered exploratory research rather than established testing methodology.
Detailed Planning of in Vitro Hematotoxicology Studies
This section briefly covers some of the details that must be addressed when planning an in vitro hematotoxicology study (84, 87, 88) .
Analytical Chemistry
There is substantial variability in the stability of different products under the conditions of the in vitro bone marrow assay, and subtle changes in the culture conditions can dramatically alter in vitro bioavailability. For example, many camptothecins show large differences in stability as a function of the species from which the culture medium serum or albumin is derived (196) (197) (198) (199) (200) . These data show that one cannot assume that chemically related compounds have identical protein binding or stability in vitro and in vivo (84, 88) . In addition, some toxicants bind extensively to the cell culture containers (201) (84, 88, (196) (197) (198) (199) (200) (201) (202) (203) (92, (204) (205) (206) (207) (208) (209) (210) . However, the metabolic capacity of the marrow stroma is small compared to liver, and it cannot produce sufficient levels of metabolite to reliably detect toxicity in the in vitro assays (1, 92 The in vitro assays of xenobiotic effects on human hematopoiesis can be viewed as prototypes of future in vitro toxicology assays that will reveal concepts and principles of clinical prediction. The hierarchical structure of stem cells and progenitors in the hematopoietic system likely reflects similar hierarchies in other renewing tissues of the body, such as the gastrointestinal mucosa. The emerging principles for prediction described in this paper will be applicable to toxicity in these other renewing tissues once clonogenic assays for epithelial progenitors are developed and the colony-stimulating factors are available. However, it seems unlikely that what is learned in predicting hematologic toxicity will be of much help in predicting toxicity to nonproliferative tissues such as the nervous system; other end points and principles of clinical prediction will be needed for these more troublesome toxicities.
